investorscraft@gmail.com

Investor's Craft

Stock Screeners
Stock Indices
Stock Valuation

Intrinsic Value of Acorda Therapeutics, Inc. (ACOR)

Previous Close$12.51
Intrinsic Value$21.91
Upside potential  +75%
Previous Close
$12.51
Intrinsic Value
$21.91
Potential        
+75%

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2022-12-31 and quarterly data as of 2023-06-30.

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

Intrinsic Value Stock Screener
Artificial intelligence value of

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2022(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %-8.1NaN
Revenue, $119NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m154NaN
Operating income, $m-35NaN
EBITDA, $m14NaN
Interest expense (income), $mNaN
Earnings before tax, $m-35NaN
Tax expense, $m31NaN
Net income, $m-66NaN

BALANCE SHEET

Cash and short-term investments, $m44NaN
Total assets, $m396NaN
Adjusted assets (=assets-cash), $m351NaN
Average production assets, $m324NaN
Working capital, $m44NaN
Total debt, $m169NaN
Total liabilities, $m302NaN
Total equity, $m94NaN
Debt-to-equity ratio1.805NaN
Adjusted equity ratio0.146NaN

CASH FLOW

Net income, $m-66NaN
Depreciation, amort., depletion, $m50NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-21NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-0NaN
Free cash flow, $m-21NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m44
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN

Company description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
HomeMenuAccount